IQM-QUANTUM-COMPUTERS
21.12.2021 12:02:08 CET | Business Wire | Press release
IQM France will collaborate closely with customers in the aviation, space, and cybersecurity verticals using IQM’s co-design approach. IQM is also part of Atos’s Scaler program, and this subsidiary will focus further on HPC integration and offer quantum accelerators to supercomputing centers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005096/en/
Through this new subsidiary, IQM joins the French quantum ecosystem that consists of world-renowned universities and research institutes and a fast-growing start-up scene and provides excellent industry infrastructure. IQM’s expertise and reach, combined with this vibrant ecosystem, will create significant opportunities for partnerships and collaboration in Europe and across the globe.
In the first phase, IQM France aims to tap into the extended talent pool of quantum students, postdocs, and experienced professionals. The plan is to start with a core team of business developers, products managers, quantum scientists, and engineers in 2022. The aim is to create a center of excellence in specific industry verticals and systematically grow in subsequent years.
IQM France’s office will be in the central hub at Spaces Les Halles on 40 rue du Louvre, Paris. Dr. Björn Pötter will take on the role of Country Manager for France in addition to his role as Global Head of Products at IQM. Dr. Pötter, who recently joined IQM, holds a PhD in physics and has extensive experience with digital technologies in the Aerospace and Cybersecurity industries. Dr. Pötter has held several international leadership positions with a focus on technology and innovation, among others at Airbus.
“I am excited to see IQM start its French operations in the Paris region, where I have been working for several years. The Paris team will build the bridge between the various IQM teams around Europe and the high-quality French quantum ecosystem. The team will enable local operations for collaborative IQM projects in strategic industrial areas,” said Dr. Pötter.
Speaking about this announcement, Dr. Jan Goetz, CEO and cofounder of IQM, said, “France plays an integral role in the quantum scientific research and has been on our roadmap for a while. I’m extremely pleased to announce the operations of our French entity today, especially at a time when the French quantum plan is gaining momentum. This French subsidiary together with our co-design teams in Bilbao and Munich and the quantum hardware and software teams in Espoo, Finland, will strengthen European quantum leadership.”
“The Paris region is proud to welcome a major European quantum computing player to the epicenter of the French quantum ecosystem. We support IQM’s local setup and growth to help them make the most of the excellent research and talent available. We are also convinced that IQM will thrive in France’s #1 aerospace region,” said Alexandra Dublanche, President of Choose Paris Region and Vice President in charge of Recovery, Attractiveness, Economic Development, and Innovation of the Paris Region.
“We are very thankful to Choose Paris Region and also Business France for the active, pragmatic, and timely support, which allowed us to set up IQM France in a very short time,” Dr. Pötter added.
In March 2021, Dr. Goetz presented on deep tech and building global tech leaders’ topics at the Scale-Up Europe event, where President Emmanuel Macron was an attendee. This presentation was part of the Scale-up Europe initiative facilitated by Sifted.
About IQM Quantum Computers:
IQM is a Pan-European leader in quantum computers.
IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers the quantum advantage through a unique application-specific co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building a quantum computer in Germany that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich, and Espoo and employs over 130 people. More information: www.meetiqm.com
Links to the quoted press releases:
- IQM opens its exclusive quantum fabrication facility in Finland
- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.
Registered office:
IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland
Choose Paris Region is the agency in charge of promoting the attractiveness of the Paris region in terms of international business. The agency works in partnership with all the region’s key players to create an appealing and coherent territorial offer, ensure promotion of the region, and offer a tailor-made service to support international businesses and professionals in their expansion.
https://www.chooseparisregion.org/
Headquarters:
Choose Paris Region, 18 rue de Londres, 75009 Paris
contact@chooseparisregion.org - +33 800 019 011
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom